Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies
NCT00003960Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 1998
- Primary completion
- Sep 2001
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan, cyclophosphamide and methylprednisolone in leukemia, multiple myeloma (MM) and myelodysplastic syndrome (MDS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: 1-year survival rate. Started Apr 1998; status: completed.
02
Drugs
busulfancyclophosphamidemethylprednisolone
03
Conditions
leukemiamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003960.